Patrick R. Verhoest

An oral SARS-CoV-2 M ^pro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson et al. · Science · 2021 · 1.8K citations · Full text

Viral Diagnostics, Worldwide Outbreak, Immunology +16

Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties

Travis T. Wager, Xinjun Hou, Patrick R. Verhoest et al. · ACS Chemical Neuroscience · 2010 · 1K citations

Pharmaceutical Science, Drug Target, Engineering +22

Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery

Travis T. Wager, Xinjun Hou, Patrick R. Verhoest et al. · ACS Chemical Neuroscience · 2016 · 564 citations

Medicinal Chemistry, Drug Target, Computational Neuroscience +15

Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes

Travis T. Wager, Ramalakshmi Y. Chandrasekaran, Xinjun Hou et al. · ACS Chemical Neuroscience · 2010 · 476 citations

Pharmaceutical Science, Vitro Adme, Drug Target +18

Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

C J Schmidt, Douglas S. Chapin, J. Cianfrogna et al. · Journal of Pharmacology and Experimental Therapeutics · 2008 · 284 citations